Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

A randomized trial of stress management for the prevention of new brain lesions in MS.

Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, Siddique J, Jin L, Daikh D, Pelletier D.

Neurology. 2012 Jul 31;79(5):412-9. doi: 10.1212/WNL.0b013e3182616ff9. Epub 2012 Jul 11.

PMID:
22786596
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
[PubMed - indexed for MEDLINE]
3.

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.

Arch Neurol. 2012 Oct;69(10):1259-69.

PMID:
22751847
[PubMed - indexed for MEDLINE]
4.

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.

Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, Scotti R, Falini A, Sormani MP, Comi G, Filippi M.

Neurology. 2009 Dec 1;73(22):1842-8. doi: 10.1212/WNL.0b013e3181c3fd5b.

PMID:
19949030
[PubMed - indexed for MEDLINE]
5.

Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?

Burns MN, Nawacki E, Kwasny MJ, Pelletier D, Mohr DC.

Psychol Med. 2014 Jan;44(2):349-59. doi: 10.1017/S0033291713000755. Epub 2013 May 17.

PMID:
23680407
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

Neurology. 2007 Apr 24;68(17):1390-401.

PMID:
17452584
[PubMed - indexed for MEDLINE]
8.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825
[PubMed - indexed for MEDLINE]
9.

Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.

Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.

Arch Neurol. 2005 Dec;62(12):1843-7.

PMID:
16344342
[PubMed - indexed for MEDLINE]
10.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
[PubMed - indexed for MEDLINE]
11.

The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.

Paolillo A, Piattella MC, Pantano P, Di Legge S, Caramia F, Russo P, Lenzi GL, Pozzilli C.

J Neurol. 2004 Apr;251(4):432-9.

PMID:
15083288
[PubMed - indexed for MEDLINE]
12.

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Poppe P, de Vos M, Lasri F, Bauer L, Dahms S, Wagner K, Pohl C, Sandbrink R.

Arch Neurol. 2007 Sep;64(9):1292-8.

PMID:
17846268
[PubMed - indexed for MEDLINE]
13.

Defining interferon beta response status in multiple sclerosis patients.

Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.

Ann Neurol. 2004 Oct;56(4):548-55.

PMID:
15389896
[PubMed - indexed for MEDLINE]
14.

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.

Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.

BMC Neurol. 2006 May 23;6:19.

PMID:
16719908
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH.

Neurology. 2010 Jun 8;74(23):1860-7. doi: 10.1212/WNL.0b013e3181e24373.

PMID:
20530322
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.

Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ.

Neurology. 2011 Oct 25;77(17):1611-8. doi: 10.1212/WNL.0b013e3182343274.

PMID:
22025459
[PubMed - indexed for MEDLINE]
17.

Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.

Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S.

Neurology. 2000 May 9;54(9):1741-5.

PMID:
10802778
[PubMed - indexed for MEDLINE]
18.

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.

Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team.

Neurology. 2012 Apr 10;78(15):1171-8. doi: 10.1212/WNL.0b013e31824f7fdd. Epub 2012 Mar 28.

PMID:
22459680
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.

Moraal B, van den Elskamp IJ, Knol DL, Uitdehaag BM, Geurts JJ, Vrenken H, Pouwels PJ, van Schijndel RA, Meier DS, Guttmann CR, Barkhof F.

Ann Neurol. 2010 May;67(5):667-75. doi: 10.1002/ana.21958.

PMID:
20437564
[PubMed - indexed for MEDLINE]
20.

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.

Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, Yang M, Hulme A, O'Connor P, Miller DH.

J Neurol. 2004 Apr;251(4):407-13.

PMID:
15083284
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk